

ARTICLE OPEN



Thy1-ApoE4/C/EBP β double transgenic mice act as a sporadic model with Alzheimer's disease

Zhengjiang Qian¹, ZhiHao Wang², Bwei Li³, Xin Meng¹, Zhonghua Kuang⁴, Yanjiao Li¹, Yongfeng Yang⁴ and Keqiang Ye¹✉

© The Author(s) 2024

Early onset familial Alzheimer's disease (FAD) with APP, PS1/2 (presenilins) mutation accounts for only a small portion of AD cases, and most are late-onset sporadic. However, majority of AD mouse models are developed to mimic the genetic cause of human AD by overexpressing mutated forms of human APP, PS1/2, and/or Tau protein, though there is no Tau mutation in AD, and no single mouse model recapitulates all aspects of AD pathology. Here, we report Thy1-ApoE4/C/EBP β double transgenic mouse model that demonstrates key AD pathologies in an age-dependent manner in absence of any human APP or PS1/2 mutation. Using the clinical diagnosis criteria, we show that this mouse model exhibits tempo-spatial features in AD patient brains, including progressive cognitive decline associated with brain atrophy, which is accompanied with extensive neuronal degeneration. Remarkably, the mice display gradual A β aggregation and neurofibrillary tangles formation in the brain validated by A β PET and Tau PET. Moreover, the mice reveal widespread neuroinflammation as shown in AD brains. Hence, Thy1-ApoE4/C/EBP β mouse model acts as a sporadic AD mouse model, reconstituting the major AD pathologies.

Molecular Psychiatry (2024) 29:3040–3055; <https://doi.org/10.1038/s41380-024-02565-x>

INTRODUCTION

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is the most common cause of dementia. The featured hallmarks of AD pathology include diffuse and neuritic plaques, which are mainly composed of the amyloid- β (A β) peptide, and neurofibrillary tangles (NFT), consisted of filamentous aggregates of hyperphosphorylated and truncated Tau proteins [1]. These misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response and release of inflammatory mediators, which contribute to disease progression [2]. Moreover, loss of neuronal synaptic density and synapses signifies another crucial feature of the disease that takes place before extensive neuronal loss [3, 4]. Notably, the memory and cognitive decline observed in AD patients correlates better with the synaptic pathology than either senile plaques or NFT [5–9].

The risk of AD is 60–80% dependent on heritable factors, of which ApoE4 reveals the strongest association with the disease [10]. ApoE4 significantly increases the risk for both early-onset and late-onset AD [11, 12]. ApoE4 increases AD risk in a dose-dependent manner, individuals that are homozygous for ApoE4 alleles are eight times more likely to develop AD than are homozygotes for ApoE3. However, ApoE4 is neither necessary nor sufficient to cause AD [13]. The proposed mechanisms are multifactorial, including both A β -dependent effects, i.e. modulation of A β levels, aggregation, neurotoxicity and neuroinflammation, and A β -independent effects, i.e. neuronal development, brain

activity and lipid metabolism [14]. While A β is continuously generated in the brain, it is efficiently eliminated under physiological conditions. Markedly, A β clearance is slower in ApoE4-TR mice than ApoE3-TR mice [15]. In addition, young ApoE4 carriers show an increased inflammatory response that may relate to AD risk later in life [16]. ApoE is physiologically expressed in glia cells in the brain [17], but it is induced in neurons under stresses [18–20], and neuronal ApoE4 is neurotoxic [21]. Single-cell sequence shows that human neurons in the brain physiologically express ApoE [22]. Further, neuronal ApoE upregulates MHC-1 expression to drive neurodegeneration in AD [23].

C/EBP β (CCAAT/enhancer-binding protein β), an important transcription factor in the differentiation and maturation of adipocytes, mediates inflammatory cytokine expression [24] and is progressively escalated in neurons with aging [25]. It mediates AEP (asparagine endopeptidase, also called legumain, gene name: *LGMM*) expression in an age-dependent manner [26]. AEP acts as a δ -secretase that primarily cleaves both APP and Tau at N585 and N368 residues, respectively, stimulating A β production and amyloid pathology and NFT. Deletion of AEP or C/EBP β from AD mouse models substantially diminishes AD pathologies, restoring the cognitive functions [27–29]. A β and inflammatory cytokine IL-6 additively activate C/EBP β [30]. Recently, we report that C/EBP β functions as a crucial transcription factor for ApoE and regulates its mRNA levels in an age-dependent way [31]. Knockout of C/EBP β in AD mouse models diminishes ApoE expression and A β pathologies, whereas overexpression of C/EBP β accelerates AD

¹Faculty of Life and Health Sciences, Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen 518055 Guangdong, China. ²Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province 430060, China. ³Shenzhen Institute of Advanced Technology, University of Chinese Academy of Science, Shenzhen, Guangdong Province 518055, China. ⁴Paul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen 518055 Guangdong, China.

✉email: kq.ye@siat.ac.cn

Received: 2 November 2023 Revised: 10 April 2024 Accepted: 15 April 2024

Published online: 24 April 2024

pathologies. Remarkably, C/EBP β selectively promotes more ApoE4 expression than ApoE3 in human neurons, in alignment with higher activation of C/EBP β in human AD brains with ApoE4/4 compared to ApoE3/3 [31]. Furthermore, neuronal ApoE4 and 27-hydroxycholesterol activate C/EBP β / δ -secretase pathway via neuronal secreted A β or inflammatory cytokines. 27-hydroxycholesterol strongly activates C/EBP β / δ -secretase pathway in human ApoE4-TR mice and triggers AD pathologies and cognitive deficits [32]. Consistent with its role in above findings, C/EBP β elevation in microglia also exacerbates Tau-driven AD pathology [33]. In addition to ApoE4 and LGMN, we showed that C/EBP β mediates APP, MAPT and BACE1 mRNA expression in neurons as well. The escalated APP and Tau proteins are subsequently cleaved by active AEP, resulting in A β accumulation and Tau aggregation and impaired synaptic plasticity. ApoE4 is elevated in neurons under stress and augmented in human AD neurons [18–20, 31], and C/EBP β is highly expressed in aged neurons and AD brains [26]. Therefore, we developed a neuronal specific Thy1-ApoE4/C/EBP β transgenic mice to simulate the events in human AD brain, and found neuronal ApoE4 drives C/EBP β , triggering AD pathology cascade in this mouse model [34].

Dozens of AD mouse models have been developed to mimic the genetic cause of human AD, and the transgenic mice overexpress mutated forms of human APP, PS1/2, and/or Tau. Many of the transgenic AD models exhibit A β aggregates, neuronal loss, gliosis and Tau pathology, associated with cognitive impairments, but no single AD model recapitulates full spectrum of AD pathology [35]. Hence, proper sporadic AD models are urgently needed to study the mechanisms underlying AD pathogenesis, and environmental risk factors that cause sporadic AD, as well as to test the therapeutic effects of AD drug-candidates on neuropathology and cognitive functions. In this study, we employed the standard clinical diagnostic criteria for AD patients, which include MMSE (Mini-mental Stage Examination, cognitive functions), magnetic resonance imaging (MRI) analysis, cerebro-spinal fluid (CSF) A β 42/A β 40 ratio, p-Tau and total Tau levels, and A β PET and Tau PET, to fully characterize Thy1-ApoE4/C/EBP β Tg mice and compare with 3xTg AD mice side-by-side. We found that this mouse model mimics human AD pathologies tempo-spatial distribution and propagation in the absence of any APP or PS1/2 mutation. Therefore, this mouse is a long-awaited innovative sporadic AD mouse model, and neuronal ApoE4 activates C/EBP β / δ -secretase pathway which might underlie the key dominant molecular mechanism driving AD pathogenesis.

RESULTS

Age-dependent learning and memory deficits in 3xTg and Thy1-ApoE4/C/EBP β Tg mice

To investigate whether the neuronal ApoE4/C/EBP β double transgenic mice mimic AD patients and display progressive learning and memory defects and act as a sporadic AD mouse model, we compared it with broadly employed genetic AD mouse model 3xTg, a triple-transgenic model harboring human patient-derived mutants PS1 (M146V), APP (Swe) and tau (P301L) transgenes [36]. Morris Water Maze (MWM) assay showed that both mouse models exhibited cognitive deficits at 6 months and got worse at 12 months of age. However, at 2 months old, neither of them demonstrated any defects. The swim speeds or travel distances were comparable among the groups, which were not changed from 2 months to 12 months of age (Fig. 1A–F), indicating that Thy1-ApoE4/C/EBP β Tg mice motor functions are normal. Novel Object Recognition test (NORT) revealed that the Exploring Index remained the same among the control mice, 3xTg and Thy1-ApoE4/C/EBP β Tg mice during the training course from 2 to 12 month of age. During the Testing phase, the Exploring Index showed both 3xTg and Thy1-ApoE4/C/EBP β Tg failed to show any enhanced interest in exploring the novel object

compared to the familiar object at 12 months, though they both demonstrated similar exploring interest to the novel object to the control mice at 2 and 6 months of age. Again, the total travel distance and time in the center were similar among the groups from 2 to 12 months (Fig. 1G–L). Hence, Thy1-ApoE4/C/EBP β double Tg mice demonstrate the same age-dependent learning and memory defects as 3xTg AD mice.

C/EBP β is a transcription factor for APP, MAPT and BACE1 [34], which are subsequently cleaved by AEP into APP N585 and Tau N368 and BACE1 N294, respectively, stimulating A β and p-Tau pathologies [27, 28, 37]. AEP enzymatic assay with the brain lysates validated AEP was highly activated in 6 and 12-month old 3xTg and Thy1-ApoE4/C/EBP β AD mouse brains (Supplementary Fig. 1A). To validate whether neuronal ApoE4 activates C/EBP β /AEP signaling in Thy1-ApoE4/C/EBP β Tg mice, we conducted immunoblotting (IB) analysis, and found that both C/EBP β and p-C/EBP β levels were higher in 3xTg and Thy1-ApoE4/C/EBP β mice than control mice at both 6 and 12 months old. Consequently, the downstream target AEP activation echoed the upstream transcription factor activities. Accordingly, APP N585 and Tau N368 were prominently cleaved by active AEP. The relative band's intensities in IB were quantified (Supplementary Fig. 1B, C).


Age-dependent brain volume reduction in 3xTg and Thy1-ApoE4/C/EBP β Tg mice

AD patient brains display cerebral atrophy and white matter changes by antemortem MRI reflect underlying neuropathology [38]. A longitudinal multimodal in vivo molecular imaging study of the 3xTg AD mouse model shows progressive early hippocampal volume loss [39]. Accordingly, we conducted an MRI assay of ApoE4/C/EBP β double Tg mice and found that both 3xTg and Thy1-ApoE4/C/EBP β Tg exhibited an age-dependent brain volumes reduction at 6 and 12 months old in both hippocampus and cortex regions. By contrast, the MRI signals remained comparable among the groups at 2 months of age (Fig. 2A, B). Nissl staining and quantification of the brain section from these mice showed that the brain volumes of 3xTg and Thy1-ApoE4/C/EBP β Tg mice decrease as compared to control mice in both regions from 6 to 12 months of age (Fig. 2C, D), correlating with MRI findings. Hence, these two AD mouse models demonstrate the brain structure atrophy in the same age.

To explore whether neurodegeneration, the cellular mechanism underlying the brain volume reduction is accountable for this effect, we performed immunofluorescent (IF) co-staining with TUNEL (red) and NeuN (green) on the brain sections and found that gradual TUNEL fluorescent signals escalation in both 3xTg and Thy1-ApoE4/C/EBP β Tg mice compared to control mice starting from 6 months old and apoptotic activities increased up to approximately 30% of neurons at 12 months old in both hippocampus and cortex regions (Supplementary Fig. 2A, B). Next, we also conducted IB assay and found that the levels of PSD95 and synaptophysin, two well-characterized postsynaptic and presynaptic biomarkers, were significantly decreased at 12 months old in both 3xTg and Thy1-ApoE4/C/EBP β Tg mice versus control mice, indicating extensive synaptic loss in the brains of both AD mouse models (Supplementary Fig. 2C, D). These molecular events temporally fit with the brain structural loss by MRI.

Age-dependent A β PET signal escalation in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice

PET imaging can quantitatively map amyloid accumulation in living amyloid precursor protein (APP) transgenic mice [40]. To side-by-side compare A β aggregation pathology in live brains of the AD mouse models, we used ¹⁸F-florbetapir (AV45) as a PET tracer to probe the A β plaque deposition. Noticeably, 3xTg and Thy1-ApoE4/C/EBP β Tg mice exhibited significantly A β PET signals elevation at 6 months of age, which were further augmented at 12 months old as compared to control mice. The images from



coronal, transverse and sagittal views demonstrated the age-dependent PET signals escalation (Fig. 3A, B). IF staining with anti-Aβ 4G8 antibody showed that Aβ aggregates were demonstrable at 2 months old and the accumulates gradually grew and the sizes

became larger and larger in both 3xTg and Thy1-ApoE4/C/EBPβ Tg mice from 6 to 12 months of age (Fig. 3C). Anti-Aβ and Thioflavin S (ThS) co-staining revealed that the aggregated Aβ in the brain sections from 3xTg and Thy1-ApoE4/C/EBPβ Tg mice were

Fig. 1 Age-dependent spatial learning and memory deficits in 3xTg and Thy1- ApoE4/C/EBP β Tg mouse. **A** Diagram showing experiment of Morris Water Maze (MWM). Latency to mount the submerged platform (left panel) and percentage of time in platform quadrant (right panel) in MWM assay with mice at 2-month **B**, 6-month **C** and 12-month **D** of age ($n = 6$, $*p < 0.05$, compared with Non Tg mice). Swim speed **E** and total distance **F** in probe trial was similar among the mice at all ages. Motor function is unchanged in 3xTg and Thy1- ApoE4/C/EBP β Tg mouse. **G** Diagram showing experiment of Novel Object Recognition Test (NORT). Exploring index of mice at 2-month **H**, 6-month **I** and 12-month **J** of age. ($n = 6$, $*p < 0.05$, $**p < 0.01$, compared with Non Tg mice). Total distance **K** and time spend in the center **L** were comparable to these mice at all ages.





Fig. 2 The brain volume is reduced in an age-dependent manner in 3xTg and Thy1- ApoE4/C/EBP β Tg mouse. **A** Representative MRI images at coronal, transverse and sagittal sections of Non Tg, 3xTg and Thy1-ApoE4/C/EBP β Tg mice at 2-, 6- and 12-month of age. **B** Relative quantification of hippocampal and cortical volumes by MRI. ($n = 3$, $*p < 0.05$, compared with Non Tg). **C** Representative Nissl staining of brain sections of 3xTg and Thy1-ApoE4/C/EBP β Tg mice at 2-, 6- and 12-month of age. Scale bar, 1 mm. **D** Relative quantification of hippocampal and cortical volumes by Nissl staining. ($n = 3$, $*p < 0.05$, compared with Non Tg).



pathological β -sheet inclusions (Fig. 3D). Anti-A β and AV45 co-staining also validated the A β proteinaceous aggregates were similar folding conformation, corroborating with the *in vivo* PET imaging. Markedly, human A β plaques in 3xTg appeared

fragmented and loose, whereas mouse A β plaques were tighter and slightly smaller (Fig. 3E). Next, we quantitatively analyzed human and mouse A β 42/40 ratios in the CSF from 3xTg and Thy1-ApoE4/C/EBP β Tg mice, respectively and found that A β 42/40

Fig. 3 Age-dependent increase of A β pathology in 3xTg and Thy1-ApoE4/C/EBP β Tg mice. A Representative A β PET images showing the A β plaque deposition in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice at 2-, 6- and 12-month of age. The brain region was labeled with white circle. **B** Relative quantification of A β PET standard uptake value ratio (SUVR) in (A) ($n = 3$ mice, $**p < 0.01$, compared with Non Tg). **C** Representative of A β immunostaining images in the hippocampus of 3xTg and Thy1-ApoE4/C/EBP β Tg mice at 2-, 6- and 12-month age. Scale bar 500 μ m for top panels, 20 μ m for bottom panels. **D** and **E**. Co-staining of A β plaque with ThS **D** and A β plaque with AV45 **E** in brain of 3xTg and Thy1-ApoE4/C/EBP β Tg mice. Scale bar, 20 μ m. **F** Levels of A β 42, A β 40 and ratio of A β 42/A β 40 in the CSF of 3xTg and Thy1-ApoE4/C/EBP β Tg mice. ($n = 3$, $*p < 0.05$, $**p < 0.01$, $***p < 0.001$).

ratios were age dependently decreased in both 3xTg and Thy1-ApoE4/C/EBP β Tg mice (Fig. 3F). Moreover, coronal section and sagittal section staining with anti-A β revealed extensive A β plaque deposits in the forebrain with cortex most abundant (Supplementary Fig. 3A–C).

Mouse A β has been questioned to aggregate into pathological fibrils, though extensive previous studies support that mouse A β and mouse Tau undeniably aggregate into amyloid deposits [41–43], mimicking the pathological features in human AD patient brains. To further characterize accumulated A β structures from the two AD mouse models, we isolated the A β inclusions from the brain and performed electron microscope (EM) analysis. They both exhibited similar fibrillary structures (Supplementary Fig. 4A, B). They displayed smeared bands with large molecular weights on the IB SDS-PAGE gels, indicating the aggregated molecules (Supplementary Fig. 4C). Quantification showed mouse A β 42 and 40 levels age-dependent elevation and A β 40 concentrations in Thy1-ApoE4/C/EBP β Tg mice were significantly higher than control mice starting at 6 months old, and further augmented at 12 months old, whereas mouse A β 42 levels in Thy1-ApoE4/C/EBP β Tg mice only significantly higher than control mice at 12 month old. By contrast, human A β 42 from 3xTg were gradually increased at both 6 and 12 months old, and both of which were significantly higher than 2 months old. On the other hand, human A β 40 at 12 months old was higher than 2 months old (Supplementary Fig. 4D). In the insoluble fractions, we found that both mouse A β 42 and A β 40 levels from Thy1-ApoE4/C/EBP β mice were much more abundant at 6 and 12 months than control mice, and human A β 42 and 40 in 3xTg mice at 6 and 12 months old were significantly higher than 2 months old (Supplementary Fig. 4E). Aggregated A β fibrils are neurotoxic. To compare whether isolated A β aggregated from these mice display similar actions, we prepared primary neuronal cultures and incubated with A β aggregated (2 μ g) from the 2 AD mouse models, and IF co-staining showed that A β induced AT8-positive p-Tau signaling in the treated neurons. They also elicited extensive neuronal apoptosis as revealed by TUNEL staining. Noticeably, they triggered AEP activation, and Tau N368 fragmentation in the treated neurons (Supplementary Fig. 4F–H), supporting that purified A β aggregates are neurotoxic and provoking Tau proteolytic cleavage and hyperphosphorylation in neurons.

Mouse-derived A β aggregates spread in the brain of APP/PS mice

Intracerebral injection of dilute, A β -containing brain extracts from AD patients or human APP transgenic mice induces cerebral β -amyloidosis and associated pathology in APP transgenic mice in a time- and concentration-dependent manner [44]. To assess whether mouse A β aggregates can also spread in 2-month old APP/PS1 host mouse brain, we prepared the A β extracts from 3xTg and Thy1-ApoE4/C/EBP β mouse brains and injected into the hippocampus. In 2 months, we found induced A β deposits primarily in the injected hippocampus and most induced A β deposits were diffuse (Fig. 4A–C). Noticeably, Iba-1 and GFAP IF signals were strongly increased in the hippocampus in host mouse brains after A β inoculation as compared to vehicle control, indicating pronounced microglia activation and astrogliosis (Fig. 4D, E), consistent with previous observations [44]. Next, we

monitored A β propagation in 3xTg and Thy1-ApoE4/C/EBP β mouse brains at 2, 6 and 12 months old, respectively, and found that intraneuronal A β signals were primarily enriched in the forebrain and frontal cortex at 2 months, and the A β -positive neurons gradually increased in the cortex and hippocampus at 6 months, and different A β plaque deposits were demonstrable in these brain regions at 12 months of age. The heat map is shown in Fig. 4F. Therefore, human A β in 3xTg and mouse A β in Thy1-ApoE4/C/EBP β mice are originated from the intraneuronal accumulation to extra-cellular plaque deposition in the forebrain, mimicking A β propagation in AD patients.

Age-dependent Tau PET signals in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice

To compare the Tau-laden neurofibrillary tangle pathology between 3xTg and Thy1-ApoE4/C/EBP β mice, we conducted neuroimaging to examine Tau pathology in live animals using 18 F-AV1451, as a PET tracer for Tau aggregates, and found the radioactive intensities progressively increased in coronal, transverse and sagittal views in both AD mouse models as compared to control mice. Quantification showed that the relative SUVR (standard uptake value ratio) significantly elevated versus control mice at 6 months of age, which was further augmented at 12 months old in both AD mouse models (Fig. 5A, B). IF staining revealed that AT8 fluorescent activities in AD mouse models grew with aging and Tau hyperphosphorylation signals were much higher at 6 and 12 months of age compared to 2 months old 3xTg and Thy1-ApoE4/C/EBP β mice (Fig. 5C, D). IF co-staining validated that AT8 positive Tau aggregates were ThS positive fibrillary tangles, which were further confirmed by AV1451 cold PET tracer staining (Fig. 5E, F). In addition, we quantitatively analyzed total Tau and p-Tau 181 in the CSF from 3xTg and Thy1-ApoE4/C/EBP β Tg mice, and found that both total Tau and p-Tau 181 increased in an age dependent manner (Fig. 5G). Therefore, mouse Tau in Thy1-ApoE4/C/EBP β mice also mimic human Tau in 3xTg aggregate into neurofibrillary tangles with aging.

Mouse-derived Tau aggregates are infectious and neurotoxic

Mouse Taus show 89% identities with human Taus, and they were questioned to aggregate into pathological fibrils. Previous study supports that mouse Tau indisputably aggregate into amyloid deposits and NFT [45], mimicking the pathological features in human AD patient brains. To interrogate whether mouse Tau in Thy1-ApoE4/C/EBP β mice demonstrates similar paired helical fibrils, we prepared Tau aggregates from both 3xTg and Thy1-ApoE4/C/EBP β mouse brains and EM images revealed that both human and mouse Tau aggregates displayed similar fibril structures (Fig. 6A, B). Quantification indicated that mouse Tau (mTau) levels in soluble fractions exhibited age-dependent escalation with more abundant mTau in Thy1-ApoE4/C/EBP β mice than control mice at 6 and 12 months of age, and p-Tau 181 levels in Thy1-ApoE4/C/EBP β mice were significantly higher in control mice. Both total hTau and p-Tau181 levels in 3xTg also displayed augmentation with aging (Fig. 6C). In insoluble fractions, Tau and p-Tau levels for both human and mouse progressively escalated from 2 to 6 and to 12 months old (Fig. 6D). It is worth noting that these Tau aggregates elicited Tau accumulation in human Tau stable transfected HEK293-K18 cells, indicating that mouse Tau simulates human Tau in triggering Tau aggregation in intact cells




Fig. 4 A β aggregates extracted from 3xTg and Thy1-ApoE4/C/EBP β Tg mice induce endogenous amyloid- β accumulation in APP/PS1 mice. **A** Diagram showing in vivo function assay of A β aggregates isolated from 3xTg and Thy1-ApoE4/C/EBP β Tg mice. A β aggregates were extracted from cortex and injected into hippocampus of APP/PS1 mouse. After 2 months of injection, the mice were sacrificed for histological analysis in brain. **B** Representative of A β plaque immunostaining images in the hippocampus of APP/PS1 mice inoculated with A β aggregates isolated from 3xTg and Thy1-ApoE4/C/EBP β Tg mice. Scale bar 500 μ m. **C** Relative quantification of A β plaque number in **B**. **D** Representative of IBA1 (left two panel) and GFAP (right two panel) immunostaining images in hippocampus of APP/PS1 mice inoculation with A β aggregates. Scale bar 500 μ m for column 1 and 3, 20 μ m for column 2 and 4. **E** Relative quantification of IBA1 and GFAP fluoresce intensity in **D**. **F** Schematic drawings representing the distribution of A β positive neurons and A β plaque in 3xTg and Thy1/ApoE3/C/EBP β transgenic mice at the age of 2-, 6- and 12-month of age. Note the age-dependent increase in the number of A β (4G8) positive neurons in the cortex and hippocampus. CA1: CA1 hippocampal subfield, CA3 CA3 hippocampal subfield, DG dentate gyrus, Ect ectorhinal cortex, M motor cortex, S sensory cortex, Small dots = 5–10 positive neurons (2-month age), medium-size dots = 20–40 positive neurons (6-month age), star = A β plaque at different size (12-month age).





Fig. 5 Age-dependent increase of Tau pathology in 3xTg and Thy1-ApoE4/C/EBP β Tg mice. **A** Representative Tau PET images showing the Tau deposition in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice at 2-, 6- and 12-month of age. 18F-AV1451 was used as a PET tracer of Tau aggregates. **B** Relative quantification of Tau PET standard uptake ratio (SUVR) in **A** ($n = 3$ mice, $**p < 0.01$, compared with Non Tg). **C** Representative of AT8 immunostaining images in the hippocampus of 3xTg and Thy1-ApoE4/C/EBP β Tg mice at 2-, 6- and 12-month of age. The Non Tg mice have no AT8 signals at all ages. Scale bar, 20 μm . **D** Relative quantification of AT8 positive neurons in **C**. ($n = 3$ mice, $*p < 0.05$, $**p < 0.01$). **E** Co-staining of AT8 with ThS in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice. Scale bar 20 μm . **F** Co-staining of AT8 with AV1451 in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice. Scale bar 20 μm . **G** Levels of pTau181 and total Tau in the CSF of 3xTg (Top panels) and Thy1-ApoE4/C/EBP β Tg mice (Bottom panels). ($n = 3$ mice, $*p < 0.05$, $**p < 0.01$).



(Fig. 6E, F). They both exhibited smear aggregation in SDS-PAGE gels and demonstrated a time-dependent degradation by proteinase K (Fig. 6G). Moreover, they also induced endogenous Tau hyperphosphorylation and neuronal apoptosis in primary

neuronal cultures. As expected, both of them stimulated AEP activation and Tau N368 fragmentation as well (Fig. 6H-J), underscoring that mouse Tau like human Tau aggregates are infectious and neurotoxic.

Fig. 6 Characterization of Tau aggregates in 3xTg and Thy1-ApoE4/C/EBP β Tg mice. **A** Diagram showing the isolation of soluble and insoluble Tau in the brain tissues of 3xTg and Thy1-ApoE4/C/EBP β Tg mice. **B** Representative electron microscope images of Tau insoluble fraction extracted from the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice. Scale bar 100 nm. **C** ELISA assay of soluble Tau levels in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice at different ages. ($n = 3$ mice, $*p < 0.05$, $**p < 0.01$). **D** ELISA assay of insoluble Tau levels in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice at different ages. ($n = 3$ mice, $*p < 0.05$, $**p < 0.01$). Tau aggregates (2 μ g) from the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice were transduced into HEK293-K18 cells stably expressing GFP-tagged Tau RD (repeat domain), After 24 h of transduction, the insoluble Tau inclusions in cells were imaged **E** and quantified **F** under microscopy. ($***p < 0.01$ as compared with vehicle). **G** Tau aggregates (5 μ g) extracted from the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice were digested with Protease K (1 μ g/ml) at different time points, and then immunoblotted with Tau antibody. Representative immunostaining images of AT8 **H** and TUNEL I, AEP and Tau N368 **J** in primary rat neurons treated with Tau aggregates (2 μ g) extracted from the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice. Scale bar 20 μ m.

IF co-staining studies showed that Tau N368 and AT8 fluorescent intensities elevated with aging in the hippocampus of both 3xTg and Thy1-ApoE4/C/EBP β mouse brains (Supplementary Fig. 5A, B). T22, a specific antibody for aggregated Tau tangles, and Tau N368 co-staining also supported that AEP-truncated Tau N368 co-localized with T22 signals that were gradually augmented in an age-dependent manner in both 3xTg and Thy1-ApoE4/C/EBP β mice (Supplementary Fig. 5C, D). Thus, AEP is progressively activated in these AD mouse brains, cleaving Tau N368 that elicits Tau hyperphosphorylation and aggregation, consistent with our previous findings [27]. Tau lesion in AD originates in the locus coeruleus (LC) neurons, which subsequently spread to entorhinal cortex (EC), and then to hippocampus (HC) [46]. To explore whether Tau pathology propagate in mouse models in a similar pathway, we monitored Tau pathology spreading routes. LC neurons were labeled with anti-DBH (Dopamine β -hydroxylase), a marker for norepinephrine neurons. IF co-staining revealed AT8 and T22 fluorescent signals were detectable at 2 months old, and these signals augmented with aging in the LC regions in both AD mouse models. At 6 months old, AT8 and T22 signals were demonstrable in EC and HC (Supplementary Fig. 6). Human Tau pathologies appeared stronger than mouse counterpart, which might be due to human Tau is Tau P301S mutant in 3xTg, whereas mouse Tau in Thy1-ApoE4/C/EBP β mice is wild-type.

Mouse-derived Tau aggregates spread in the brains of 3xTg and Thy1-ApoE4/C/EBP β Tg mice

To investigate whether mouse Tau aggregates could also spread in live animal's brain, we isolated Tau aggregates from the cortex from both 3xTg and Thy1-ApoE4/C/EBP β mice, and injected into the hippocampus of 3-month old Tau P301S mice. In 2 months, we found robust AT8 signals appeared in a lot of hippocampal neurons validated by both IF staining and immunohistochemistry (IHC) staining (Fig. 7A–C). Again, we also observed extensive Iba-1 and GFAP fluorescent activities in the hippocampus regions, suggesting that inoculated Tau fibrils incurs prominent microglia activation and astrogliosis (Fig. 7D, E).

Neuroinflammation is one of the key hallmarks in AD pathology. Quantitative RT-PCR (qRT-PCR) analysis showed that both IL-6 and TNF α mRNA levels were significantly increased in both 3xTg and Thy1-ApoE4/C/EBP β mice compared to control mice at 6 and 12 months old. ELISA quantification of these inflammatory cytokines in the brain lysates revealed similar augmentation patterns (Supplementary Fig. 7A, B). qRT-PCR of GFAP and Iba-1 mRNA also showed that both concentrations increased with aging with 6 and 12 months of ages significantly higher in 3xTg and Thy1-ApoE4/C/EBP β mice compared to control mice (Supplementary Fig. 7C). IF staining of the brain sections confirmed the qRT-PCR results (Supplementary Fig. 7D, E). Therefore, Thy1-ApoE4/C/EBP β mice exhibit widespread neuroinflammation like 3xTg mice, mirroring what observed in human AD patient brains.

ApoE4 promotes mouse A β polypeptide aggregation in vitro Mouse A β 42 possesses 3 different amino acids from human counterpart. Compared to human A β 42 polypeptide, mouse A β 42

are poorly aggregated into fibrils in vitro [47, 48]. To explore why mouse A β polypeptide could aggregate into plaques in Thy1-ApoE4/C/EBP β mice, we perform in vitro aggregation assay by shaking the peptides at 37 $^{\circ}$ C in vitro. Thioflavin T (ThT) fluorescent kinetic curves showed that mouse A β 42 failed to aggregate, in contrast human A β 42 aggregates in a time-dependent manner. Noticeably, mouse A β 42 started to aggregate in the presence of recombinant ApoE proteins with ApoE4 stronger than ApoE3 (Supplementary Fig. 8A). EM analysis validated mouse A β 42 formed extensive fibrils in the presence of ApoE4, whose morphologies appeared different from human counterpart (Supplementary Fig. 8B). IB analysis with these samples demonstrated that massive human A β 42 oligomers, which were also found in mouse A β 42/ApoE4 group. By contrast, the oligomer amount was decreased in ApoE3 (Supplementary Fig. 8C). Interestingly, these A β 42 oligomers also triggered significant cell death in SH-SY5Y cells, which correlated with their effects in activating AEP (Supplementary Fig. 8D, E). IB showed that both human A β 42 and mouse A β 42 oligomers strongly activates C/EBP β /AEP signaling (Supplementary Fig. 8F, G). As expected, these oligomers also strongly triggered microglia cell activation, leading to inflammatory cytokines including TNF α and IL-6 expression and secretion (Supplementary Fig. 8H, I). Hence, mouse A β 42 in Thy1-ApoE4/C/EBP β Tg mice are aggregated into amyloid plaques in the presence of ApoE4, simulating the pathological functions of human A β 42.

DISCUSSION

In the current study, we utilized the clinical diagnostic criteria for AD patients to fully characterize Thy1-ApoE4/C/EBP β Tg mice, and compared with genetic 3xTg AD mouse model side-by-side. We show that C/EBP β /AEP signaling is activated in both AD mouse models, associated with APP N585 and Tau N368 fragmentation, which correlates with potent AEP enzymatic activities. Consequently, A β PET and Tau PET validate abundant A β plaques and Tau tangles deposited in the brains, which become apparent at 6 months old in both AD models. The A β and Tau pathologies temporally couple to C/EBP β /AEP biochemical events, underscoring that APP and Tau fragmentation by AEP is accountable for the amyloid and Tau pathologies. Moreover, the mouse A β and Tau aggregates isolated from Thy1-ApoE4/C/EBP β Tg mice are structurally similar to human counterparts purified from 3xTg mice. In addition, they are all infectious and neurotoxic. Inoculation of these isolated pathological fibrils into the hippocampus of APP/PS1 or Tau P301S host mice spread the A β and Tau pathologies to other regions, associated with widespread neuroinflammation. In alignment with human fibrils propagation, both mouse A β and Tau pathologies spread in a similar manner as in human AD patient. Specifically, A β pathology starts from the forebrain cortex to propagate to the whole cortex, then to the midbrain, and subsequently to the brain stem; by contrast, Tau lesion originates from the LC neurons in the brain stem to EC then to HC, finally spread to the whole cortex [46]. Our analysis shows that mouse A β and Tau reveal the similar propagation routes in




Fig. 7 **In vivo functions of Tau aggregates extracted from 3xTg and Thy1-ApoE4/C/EBPβ Tg mice.** **A** Diagram showing in vivo function assay of Tau aggregates isolated from 3xTg and Thy1-ApoE4/C/EBPβ Tg mice. **B** Representative of AT8 immunostaining images in the hippocampus of Tau P301S mice inoculation with Tau aggregates isolated from 3xTg and Thy1-ApoE4/C/EBPβ Tg mice. Scale bar 500 μm for left panels, 20 μm for right panels. **C** Relative quantification of AT8 positive neurons in **B**. ($n = 3$ mice, $*p < 0.05$, $**p < 0.01$). **D** Representative of IBA1 (left two panels) and GFAP (right two panels) immunostaining images in the hippocampus of Tau P301S mice inoculation with Tau aggregates isolated from 3xTg and Thy1-ApoE4/C/EBPβ Tg mice. **E** Quantification of IBA1 and GFAP fluorescence intensity in **D**. ($***p < 0.01$ as compared with PBS).

Thy1-ApoE4/C/EBPβ Tg mice to human counterparts in 3xTg AD mice. Accordingly, MRI demonstrates that both animal models exhibit the brain volume reduction at the similar time points. Consequently, the spatial memory and object memory defects

take place at 6-month old and 12-month old in both models, respectively. Therefore, Thy1-ApoE4/C/EBPβ model mimics the development of sporadic AD pathologies more closely, and this model is better suited for studying the multifactorial and

non-genetic aspects of AD pathogenesis. In contrast, the commonly used mouse models, including 3xTg, 5xFAD and Tau P301S, carry several mutant genes associated with familial AD, representing the rare familial form of the disease. While valuable for studying the genetic aspects of AD, these models do not fully capture the complexity of sporadic AD.

MMSE, MRI, CSF A β 42 / A β 40 ratio, p-Tau and total Tau levels, A β PET and Tau PET signals are standard clinical diagnosis protocols for AD patients. We have shown that CSF mouse A β 42/A β 40 ratios reduce in Thy1-ApoE4/C/EBP β Tg mice, similar to human A β 42/A β 40 ratios decrease in 3xTg mice, supporting that mouse A β 42 is gradually aggregated and accumulated in the brain. These findings are in alignment with progressively augmented A β PET signals in Thy1-ApoE4/C/EBP β Tg mice (Fig. 3). Moreover, our previous results showed that CSF Tau N368/Tau ratios in AD patients better reflect the individual cognitive deficits and Tau pathologies than p-Tau 181 and p-Tau217 levels [49, 50]. Consistently, we observed age-dependent Tau N368 fluorescent signals escalation in both 3xTg and Thy1-ApoE4/C/EBP β Tg mice, tightly correlating with gradual elevation of AT8 and T22 activities (Supplementary Fig. 5). Because Tau N368 is prior to Tau hyperphosphorylation and NFT pathology [27]. Conceivably, Tau N368 is a promising biomarker for early diagnosis of AD.

Synaptic dysfunction is among the best correlates for the memory and cognitive changes that characterize AD [3, 4]. The dendritic arborization and spines are distinctly attenuated in the hippocampal CA1 neurons in 9 months old Thy1-ApoE4/C/EBP β Tg mice versus the WT littermates of the same age. In addition, EM study shows that the synapses are evidently reduced in Thy1-ApoE4/C/EBP β Tg mice with aging. Consistently, the electrophysiology analysis demonstrates that synaptic plasticity (long-term potentiation, LTP) in Thy1-ApoE4/C/EBP β Tg mice is diminished in an age-dependent manner [34]. Hence, Thy1-ApoE4/C/EBP β Tg mice display synaptic plasticity defects with impaired LTP, correlating with wide-spread synapse loss and reduced dendritic spines. 3xTg mice reveal deficits in long-term synaptic plasticity that correlates with the accumulation of intraneuronal A β , suggesting a pathogenic role in sabotaging synaptic plasticity by intraneuronal A β [36]. LTP is severely impaired in the 6-month-old 3xTg AD mice. The intraneuronal accumulation of A β underlies the observed synaptic dysfunction. We found that extensive A β -positive neurons and abundant A β plaques deposited in the hippocampus of 6-month old 3xTg and Thy1-ApoE4/C/EBP β mice (Figs. 3, 4).

In order to address whether mouse A β or Tau could aggregate into pathological fibrils, we provide a plethora of evidence showing that ThS and cold PET tracers AV45 and AV1451 form fluorescent complex in the β -sheet enriched fibrils (Figs. 3, 5), which are corroborated by EM analysis (Fig. S4, Fig. 6). In addition, these isolated amyloid and Tau aggregates are infectious and neurotoxic, similar to their human counterparts purified from 3xTg mice. The A β and Tau proteins misfold, self-assemble, and propagate by an endogenous mechanism closely resembling the seeded aggregation and spread of the prion proteins [51–53]. A β plaques disrupt circuits and neighboring brain cells [54, 55], but A β also forms small, soluble, oligomeric assemblies that impair the function of neurons and glia [56, 57]. Inoculation of the amyloid or Tau aggregates into APP/PS1 or Tau P301S mice elicits A β and Tau pathology spreading (Figs. 4, 6, 7). These results are in agreement with extensive previous studies showing that mouse A β and mouse Tau undeniably aggregate into amyloid deposits and NFT [41–43, 45], mimicking the pathological features in human AD patient brains. With the aim of supporting that mouse A β and mouse Tau indeed aggregate into amyloid deposits and NFT, we employed various approaches to confirm their identities including immunoblotting and proteomics from the insoluble fractions from mouse brains, anti-A β or anti-AT8 co-staining with ThS, Gyllas-Braak Silver staining and immuno-EM [34]. Hence, mouse A β and mouse Tau can form pathological amyloid deposits and NFT as human counterparts in AD patients.

Previous studies show that mouse A β is less prone to aggregate into pathological fibrils [47, 48]. In aging APP (V717F^{+/+}) transgenic mice expressing mouse ApoE, no ApoE, or human ApoE2, ApoE3, or ApoE4, Holtzman et al. [58] demonstrate that ApoE facilitates, but is not required for, A β fibril formation in vivo. Human ApoE isoforms markedly delays A β deposition relative to mouse ApoE, with ApoE2 (and ApoE3 to a lesser extent) having a prolonged ability to prevent A β from converting into fibrillar forms [59]. In this study, it is human A β in vivo aggregation is analyzed. However, we show mouse A β alone is unable to aggregated, fitting with previous reports. On the contrast, human ApoEs prominently stimulate mouse A β fibrillization in vitro with ApoE4 stronger than ApoE3. Furthermore, the in vitro mouse fibrils are neurotoxic and trigger C/EBP β /AEP signaling activation, in addition to incurring microglia activation and inflammatory cytokines secretion (Supplementary Fig. 8). These findings shed insights into the molecular mechanism why endogenous mouse A β and Tau machinery in Thy1-ApoE4/C/EBP β Tg mice could tempo-spatially reconstitute salient features of AD pathologies in the absence of any APP or PS1/2 mutation.

AD patient brains display cerebral atrophy and white matter changes by antemortem MRI reflect underlying neuropathology. Brain volume loss correlates more strongly with tangles than with any other pathological finding [38]. MRI assay included assessment of hippocampal structural integrity [39]. Here, we show that Thy1-ApoE4/C/EBP β Tg and 3xTg mice exhibit age-dependent brain atrophy and hippocampal and cortical volume reduction validated by MRI (Fig. 2), which are consistent with temporal neuronal cell death in both mice (Supplementary Fig. 2). We find that both 3xTg and Thy1-ApoE4/C/EBP β Tg AD mice progressively develop A β and Tau pathology, with a temporal- and regional-specific profile that closely mimics their development in the human AD brain (Figs. 3, 5). A β deposits initiate in the cortex and progress to the hippocampus with aging, whereas Tau pathology is originated from the LC to EC to HC and then progresses to the cortex (Supplementary Fig. 6).

Recent anti-A β monoclonal antibody trials reveal that removing aggregated A β from the brains of symptomatic patients slows AD progression. However, the achieved clinical benefit has been modest, suggesting the need for both a deeper understanding of disease mechanisms and the importance of intervening earlier [60]. C/EBP β is a transcription factor for APP, MAPT and BACE1 [34], which are subsequently cleaved by AEP into APP N585 and Tau N368 and BACE1 N294, respectively, stimulating A β and p-Tau pathologies [27, 28, 37]. In addition, it also mediates ApoE mRNA transcription as well [31] and ApoE4 feeds back and activates C/EBP β with 27-hydroxycholesterol, driving AD pathology [32]. In our most recent study, we find that neuronal but not glial ApoE4 is essential for jointly activating this pathway with FSH [61]. Our study further confirms the toxic role of neuronal ApoE in AD pathogenesis [34, 62, 63]. Consequently, neuronal ApoE4 stimulates C/EBP β activation in Thy1-ApoE4/C/EBP β transgenic mice, promoting AD pathologies via mouse machinery. Together, our thorough characterization of the double transgenic mice supports the animal acts as a sporadic AD model and reproduces both amyloid and Tau pathologies in a regional and temporal pattern analogous to AD patients, which makes it very valuable for longitudinal studies. Conceivably, this sporadic AD mouse model will provide an innovative tool for therapeutic agents' treatment investigation.

MATERIALS AND METHODS

Mice and reagents

Mice. The 3xTg mice, Tau P301S (line PS19) and APP/PS1 mice were originally purchased from the Jackson Laboratory (3xTg, catalog no. 008169; Tau P301S, catalog no. 008169; APP/PS1, catalog no. 005864). The Thy1-ApoE4/C/EBP β transgenic mice were generated and maintained as described in our previous work [34]. The mice carrying one copy of ApoE4 and human C/EBP β genes, i.e., ApoE4/C/EBP β Tg, were used for the study

unless otherwise stated. All the mice were bred in specific pathogen-free facilities, with 12-h light/12-h dark cycle and free access to water and food, at Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS). Both male and female mice, with the age of 2, 6 and 12 months, were interchangeably used for experiments. All protocols involving experimental animal were approved by the institutional animal care and use committee at the SIAT.

Antibodies and reagents

All antibodies used in this work are listed as followed: anti-amyloid β (A β , clone, 4G8, BioLegend, 800701), anti-NeuN (Sigma Aldrich, MAB377), anti-Synaptophysin (Proteintech, 17785-1-AP), anti-PSD95 (Cell signaling technology, #3409), anti-synapsin 1 (Cell signaling technology, #5297), anti-APP (Sigma-Aldrich, MAB348), anti-APP N585 (Ye lab), anti-APP C586 (Ye lab), anti-Tau N368 (Ye lab), anti-GFAP (Invitrogen, PA516291), anti-Iba1 (Invitrogen, PA5-18039), Anti-Tau 5 (Sigma Aldrich, MAB361), anti-active AEP antibody (Cell signaling technology, #93627), MAP2 (Proteintech, 17490-1), Anti-AT8 (phospho-Tau at Ser 202, Thr205, Thermo Fisher, MN1020), Anti-C/EBP β (Santa Cruz, sc-7962), Anti-p-C/EBP β (Cell Signaling Technology, #3084) and anti-GAPDH (ProteinTech, 60004-1), anti-T22 (Millipore, ABN454). Alexa Fluor 594, 488 and 647 conjugated secondary antibodies were purchased from Jackson ImmunoResearch.

AEP substrate Z-Ala-Ala-Asn-AMC (Bachem, 4033201), DAPI (Sigma Aldrich, D9542), Mouse and Rabbit Specific HRP/DAB IHC Detection Kit (Abcam, ab236466). Human A β 40, A β 42, Tau, pTau181 and ELISA kits, pro-inflammatory cytokines TNF- α , IL-6 ELISA kits were purchased from Invitrogen. Mouse A β 40, A β 42, Tau, pTau181 and ELISA kits, pro-inflammatory cytokines IL-1 β , TNF- α , IL-6 ELISA kits were purchased from a commercial company (Aimeng Youning, Shanghai, China). Cold tracer of A β (AV-45, HY-129650) and Tau (AV-1451, HY-101184) were purchased from Med Chem Express (USA). Human and mouse A β 42 peptide were purchased from ChinaPeptides (China).

Behavioral tests

Morris water maze. Mice were trained in a round tub filled with water in an environment surrounded by extra maze cues. Each mouse was trained 3 trails/day for 5 consecutive days with a 15-min intertrial interval. The maximum trial time was 60 s, and if the mouse did not reach the platform in the allotted time, they were manually guided to do it. Following the 5 days task training, a probe trial was given, during which time the platform was removed. All trials were analyzed for latency using EthoVision XT-Video tracking software (Noldus Information Technology Co., Ltd).

Novel object recognition test (NORT). Mice subjected to NORT underwent three phases: habituation, familiarization and discrimination. In the habituation phase, each mouse was placed in a square open field (40 \times 40 \times 40 cm) individually for 10 min per day for three consecutive days. Then the animals entered into the familiarization phase. In this phase, each mouse was allowed to explore in the open field with two identical objects located in opposite and equidistant positions for 10 min. Exploration was defined as sniffing or touching the objects with the nose and/or forepaws when the nose was in contact with or directed at the object at a distance of \leq 1.5 cm. After a three-hour retention interval, the mouse returned to the open field, with one of the familiar objects replaced by a novel object. For the discrimination phase, each mouse was allowed to explore for 10 min and the time for exploring each object was recorded. Mice touching an object or facing an object within 2 cm around the object were taken as measure of object exploration behavior. To eliminate olfactory cues, the objects and field were cleaned with 75% ethanol between each trial. The exploring index was determined as: (exploration time for the novel - exploration time for the familiar object) / (total exploration time during the test session) \times 100%.

Brain volume quantification

MRI acquisition. MRI experiments were performed on a United Imaging uMR 9.4 T scanner with a standard cross coil set-up using a volume coil for excitation and quadrature mouse surface coil for signal detection (UNITED IMAGING, Shanghai, China). Mice were kept anesthetized by isoflurane, and T2-weighted images were acquired in coronal planes using a rapid acquisition with relaxation enhancement sequence with the following parameters: TR = 3500 ms; TE = 47 ms; pixel size of 0.078 mm \times 0.078 mm and slice thickness of 0.2 mm without spacing between slices. Regional volumes were determined using U_VIEWER software (UNITED IMAGING, Shanghai, China).

Nissl staining was further used for brain volume quantification as described in our previous work [34]. In brief, mice hemibrains were cut coronally at 30 μ m, and all sections were collected. Brain sections were mounted on microscope slides (Fisher Scientific) in an anterior-to-posterior order, starting from the section where the target structure first becomes visible (first section) to the section where target structure just disappears (last section). Mounted brain sections were dried at room temperature and stained with Cresyl violet (Nissl staining). Sections were stained in 0.1% Cresyl violet solution (Abcam) and mounted. Images were acquired with an Olympus VS120 virtual microscopy slide scanning system. The volume of ventricle and hippocampus were estimated using Image J.

Small animal PET

Mice were anesthetized following a standardized protocol for Radiochemistry, acquisition, and post processing. Inhalation anesthesia with isoflurane was used throughout the experiments, and PET images were recorded on a high-resolution small animal PET scanning device (microPET) with a spatial resolution of 1.0 mm. Brain emission scans were obtained in volumetric mode for the 20 min after an intravenous injection of 10–15 MBq of 18F-Florbetapir (AV45) or 18F-Flortaucipir (AV1451) in approximately 100 μ L of saline into the vein of tail. The PET images were reconstructed by using ordered-subset expectation maximization (OSEM) with 16 subsets and 5 iterations. Target-to-reference tissue (the cerebellum) standard uptake value ratio (SUVR) was calculated from a standardized target volume of interest, and was analyzed by Amide 1.0.4-1 (San Diego, CA 92101) for scaling of 18F-AV45 or 18F-AV1451 data.

CSF and serum collection

Collection of CSF from the cisterna magna was carried out as previously described [64]. In brief, the mice were deeply anesthetized by 1% pentobarbital sodium and then placed in a stereotaxic device. The skin of the neck was shaved, and the surgical site was swabbed with 10% povidone iodine, followed by 70% ethanol. A sagittal incision of the skin was made inferior to the occiput, and the subcutaneous tissue and muscles were separated under the dissection microscope. After the CSF space was visible, a glass capillary tube was inserted into the cisterna magna, and then the CSF was collected. Samples showing signs of blood contamination were centrifuged at 2000 g for 10 min at room temperature. For serum extraction, the whole-blood samples were collected from the mice and then centrifuged at 3000 g for 10 min at 4 $^{\circ}$ C. All the CSF and serum samples were stored at -80° C until use.

SiMoA assay of CSF

All the SiMoA (Single Molecular Array) assays were performed on the Quanterix SR-X analyzer (Quanterix) as previously described [65]. The concentrations of Tau, A β 40 and A β 42 in CSF were measured using the Simoa[®] Neurology 3-Plex A Advantage Kit (catalog #101995) according to the manufacturer's instructions. The concentrations of pTau-181 in CSF were measured using the Simoa[®] pTau-181 Advantage V2 Kit (catalog #103714) according to the manufacturer's instructions. CSF samples were diluted 1:100–400. All measurements were carried out in one round of experiment using the same batch of reagents.

Western blot analysis

Total protein from mouse brain tissue samples were extracted with lysis buffer (50 mM Tris, 40 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 1.5 mM Na₃VO₄, 50 mM NaF, 10 mM sodium pyrophosphate and 10 mM sodium β -glycerophosphate, pH 7.0, supplemented with a cocktail of protease inhibitors). Protein concentration of samples was measured using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific). Equal protein amounts (30 to 50 μ g) were loaded for SDS-PAGE and transferred to a polyvinylidene difluoride or nitrocellulose membrane. After blocking the nonspecific site with 5% nonfat milk for 1 h, the membrane was incubated with a specific primary antibody overnight at 4 $^{\circ}$ C and then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The immune blotting signals were visualized with an enhanced chemiluminescence (ECL) kit (Thermo Fisher Scientific, catalog no. 32209) using a chemiluminescent imaging system (Bio red). Digital images were quantified using densitometric measurement with ImageJ software.

Real-time PCR

Total RNA from brain tissue was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.

The concentration of RNA was quantified by the NanoDrop 2000c Spectrophotometer (Thermo Fisher Scientific, Rockford, IL). The first-strand cDNA was synthesized from 1 µg of total RNA using Hifair One Step RT-qPCR Kit (YEASEN Biotech, Shanghai, China). The quantitative PCR experiments were conducted on a QuantStudio Real-Time PCR system (Applied Biosystems) using Hieff® qPCR SYBR Green Master Mix (YEASEN Biotech) with gene-specific primers. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control for normalization. All reactions were performed in triplicate with three independent experiments, and the relative expression of mRNA levels was calculated using the $2^{-\Delta\Delta Ct}$ method.

Immunofluorescence staining, Thioflavin S and cold PET tracer staining

Mice were deeply anesthetized and perfused with ice-cold PBS followed by 4% PFA. The whole brain was dissected, fixed in 4% PFA overnight, dehydrated in 30% sucrose at 4 °C, embedded in OCT (optimal cutting temperature compound) (Sakura Finetek), and processed for cryosections at 20 µm. The cryosections were permeabilized and blocked in blocking buffer [0.4% Triton X-100 and 5% normal bovine serum albumin (BSA) in PBS] for 1 h at room temperature and overnight with primary antibodies overnight at 4 °C. After washing with PBS, sections were incubated with secondary antibodies labeled with Alexa Fluor 488 or 594 (Jackson ImmunoResearch Laboratories; 1:1000) for 1 h at room temperature, stained with 4',6-diamidino-2-phenylindole (DAPI) for 10 min, washed three times in PBS, and then mounted in Mounting Medium. For Thioflavin S (ThS), AV45 with Aβ or AV1451 with AT8 double staining, slides were rinsed in PBS after finishing the Aβ or AT8 first antibody and the second antibody staining. Freshly dissolved ThS, AV45 or AV1451 in 50% Ethanol and incubated the slides in ThS, AV45 or AV1451 solution at room temperature for 7 min in the dark. Then wash the slides in PBS for three times. Last, coverslips were mounted on glass slides and imaged using a confocal microscope (LSM 980, Zeiss).

Immunohistochemistry

Immunohistochemistry (IHC) was carried out following the peroxidase protocol. Briefly, tissue sections were deparaffinized in xylene, hydrated through descending ethanol concentrations, and endogenous peroxidase activity was eliminated by incubation in 3% hydrogen peroxide in methanol for 5 min. After antigen-retrieval in boiling sodium citrate buffer (10 mM), the sections were incubated with primary antibodies for overnight at 4 °C. The signal was developed using Mouse and Rabbit Specific HRP/DAB detection IHC kit (Abcam). Images were acquired using Olympus VS120 virtual microscopy slide scanning system.

ELISA assay of Aβ, Tau and cytokines

Mouse brain samples were homogenized in lysis buffer and centrifuged at 16,000 g for 20 min at 4 °C. The supernatant was for Aβ, Tau, IL6 and TNFα analyzed by ELISA kits according to the manufacturer's instructions. The insoluble protein including Aβ and Tau aggregates were extracted following the protocol as described in previous work [66, 67] and then were analyzed by ELISA kits according to the manufacturer's instructions.

Isolation of Sarkosyl insoluble Tau aggregates in brain tissue

Sarkosyl insoluble Tau were extracted as described previously [67]. Briefly, mice were euthanized by cervical dislocation in order to preserve the metabolic environment of the brain and to prevent artifacts that could alter the biochemical profiles of tau protein. Mouse brains were bisected down the midline to yield two hemispheres. The forebrain including cerebral cortex and hippocampus was separated from the hemisphere by a razor blade, and homogenized in ten volumes of Tris-buffered saline (TBS) buffer (50 mM Tris/HCl, pH 7.4, 274 mM NaCl, 5 mM KCl) containing the protease and phosphatase inhibitors with a mechanical homogenizer. Centrifuge at 27,000 g for 20 min at 4 °C. Keep the supernatant as soluble fraction of Tau. From the pellet, homogenized with 5 vol. (v/w) of high salt / sucrose buffer (0.8 M NaCl, 10% sucrose, 10 mM Tris-HCl, pH 7.4, 1 mM EGTA, 1 mM PMSF). Centrifuge at 27,000 g for 20 min at 4 °C. The supernatant was adjusted to 1% Sarkosyl and incubated for 1 h at 37 °C on orbital shaker, and centrifuged at 150,000 g for 1 h at 4 °C. The pellet was resuspended with TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA.) as Sarkosyl insoluble fraction of Tau aggregates.

Isolation of insoluble Aβ aggregates in brain tissue

Aβ species were extracted from brain homogenates as previously described [66]. In brief, equal volumes of 0.4% diethylamine (DEA) to brain homogenate were subjected to ultraspeed centrifugation at 135,000 g for 1 h at 4 °C. After neutralization, supernatant was collected and used as soluble Aβ species. The remaining pellet was then dissolved in formic acid (FA), subjected again to ultraspeed centrifugation at 109,000 g for 1 h at 4 °C, and, after neutralization, the supernatant was collected and used to analyze insoluble Aβ species.

Transduction of Tau aggregates

HEK293-K18 cells that stably expressed tau repeat domain were seeded in 6-well plates. Twenty-four h later, Tau aggregates extracted from 3xTg and Thy1-ApoE4/C/EBPβ mice (2 µg) were transfected into HEK293-K18 cells using lipofectamine-3000 (Invitrogen) according to the manufacturer's instructions. Eighteen h later, cells were fixed with 4% PFA in PBS for 10 min and then stained with DAPI for 5 min. Coverslips were mounted, sealed with nail polish, and placed at 4 °C prior to analysis under Zeiss confocal imaging system (LSM 900). To quantify percent cells positive for Tau inclusions, a total of 10 fields were analyzed. The percentage of cells with inclusions were calculated based on the number of DAPI positive nuclei.

Protease K digestion

Proteinase K (Roche) was diluted in PBS to a final concentration of 1 mg/mL and single-use aliquots were stored at -80 °C. Tau aggregates (5 µg) was added to proteinase K at a concentration of 1 µg/mL (diluted in PBS) for a final volume of 20 µL. After different time of digestion, the mixture was subjected to SDS-PAGE gel for Tau blotting.

Imaging by transmission electron microscopy

An aliquot of 5 µL of Tau or Aβ aggregates isolated from 3xTg and Thy1-ApoE4/C/EBPβ mice were deposited on carbon-coated copper grids (Electron Microscopy Sciences, Washington, PA, USA), and then negatively stained with 2% Phosphotungstic acid for 1 min. After 3 times of washing and air-dried for 5 min, grids were examined using a Hitachi-7100 transmission electron microscope operated at 80 kV.

Primary cortical neuronal cultures

For primary cortical neuron culture, the cortex of embryonic day 18 Sprague-Dawley rat embryos was dissected and digested with 0.05% trypsin for 10 min at 37 °C. The digestion was stopped by adding 20% fetal bovine serum and then centrifuged at 1000 × g for 5 min. Neurons were seeded in 6-well dishes with coverslips pre-treated with 100 µg/mL poly-D-lysine (Sigma Aldrich) after addition of neuronal plating medium containing DMEM/F12 with 10% fetal bovine serum. After 6 h of incubation, medium was replaced by Neurobasal medium (Gibco) containing serum-free B-27 (Invitrogen) and GlutaMAX (Invitrogen) and cultured in a humidified incubator with 5% CO₂ at 37 °C. At day of 15 in vitro culture, neurons were treated with Aβ or Tau aggregates extracted from 3xTg and Thy1-ApoE4/C/EBPβ mice.

Animals and hippocampal injections

APP/PS1 (2 months old) and Tau P301S (3 months old) mice were used for hippocampal injection of Aβ and Tau aggregates from 3xTg and Thy1-ApoE4/C/EBPβ mice, respectively. Mice were anesthetized with isoflurane and were unilaterally injected into the hippocampus (-2.5 mm posterior, ±2 mm lateral, -1.8 mm ventral from bregma). Either 2 µL of 5 mg/mL Aβ aggregates or 2 µL of 2.5 mg/mL Tau aggregates were delivered by using a micro syringe pump (WPI, UMP3/Micro2T, USA) with a 10 µL Hamilton syringe. The syringe was kept still for 10 min till the end of injection to allow diffusion. After 2-month of injection, mice were sacrificed for histological analysis. All protocols involving experimental animal were approved by the institutional animal care and use committee at the SIAT.

AEP activity assay

Total protein from brain tissue homogenates (10 µg) were incubated with 200 µL reaction buffer (0.1% CHAPS, 20 mM citric acid, 60 mM Na₂HPO₄, 1 mM EDTA and 1 mM DTT, pH 6.0) containing 20 µM AEP substrate Z-Ala-Ala-Asn-AMC (4-methyl-7-coumarylamide) (Bachem). The fluorescence released by substrate AMC cleavage was quantified by measuring at

460 nm in a fluorescence plate multi-mode reader (Biotex, Synergy HTX) at 37 °C for 2 h in kinetic mode.

Thioflavin T fluorescence assay

To assess coaggregation of mouse A β with human ApoE4 / ApoE3, monomeric mouse A β 42 (10 μ M) was incubated with purified ApoE4 / ApoE3 (0.1 μ M) in ThT fluorescence assay buffer (50 mM sodium phosphate buffer, pH 7.4, 50 mM NaCl, 10 μ M ThT and 0.01% sodium azide) at 37 °C with an orbital shaking. Real-time ThT fluorescence measurements were recorded every 10 min for 5 h at excitation and emission wavelengths of 440 nm and 490 nm on a Biotek microplate reader. As a positive control, ThT fluorescence measurements were also performed using human A β 42 aggregation as described above.

MTT assay

SH-SY5Y cells were seeded into 96-well culture plates at a density of 100,000 cells/well in growth medium supplemented with 10% serum. The cells were treated with aggregation of mouse A β 42, mouse A β 42/ApoE4, and mouse A β 42/ApoE3 for 24 h and then used for cell viability assay using the Cell Counting Kit-8 (Yeasen, China) following the manufacturer's protocol. The absorption was read at 570 nm using micro-plate spectrophotometer (Bio Tek).

Statistical analysis

Statistical analyses were performed with the SPSS version 13.0 software 261 package (SPSS, Chicago, IL, USA) for Windows. All data are presented as means \pm SD unless otherwise stated. When only two groups were compared, the statistical differences were assessed with the double-sided Student's t test. Sample size was determined by Power and Precision (Biostat). The number of samples per group ($n \geq 6$) is stated in the figure legends. Comparisons among multiple groups were performed using one-way analysis of variance (ANOVA) with Tukey's post hoc test. Two-way ANOVA was used for analysis of multiple groups with Tukey's multiple comparison post hoc test. For all experiments, $*p \leq 0.05$ was considered a significant difference.

DATA AVAILABILITY

All data generated or analysed during this study are included in this published article and its supplementary information files. The datasets of the current study are available from the corresponding author on reasonable request.

REFERENCES

- Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. *J Alzheimer's Dis.* 2001;3:75–80.
- Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* 2015;14:388–405.
- DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. *Ann Neurol.* 1990;27:457–64.
- Scheff SW, DeKosky ST, Price DA. Quantitative assessment of cortical synaptic density in Alzheimer's disease. *Neurobiol Aging.* 1990;11:29–37.
- Flood DG, Coleman PD. Hippocampal plasticity in normal aging and decreased plasticity in Alzheimer's disease. *Progr Brain Res.* 1990;83:435–43.
- Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. *Proc Natl Acad Sci USA.* 2001;98:12245–50.
- Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. *J Neuropathol Exp Neurol.* 1997;56:933–44.
- Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. *Ann Neurol.* 1991;30:572–80.
- Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. *Neurobiol Aging.* 1995;16:285–98. discussion 298–304
- Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch  telat G, Teunissen CE, et al. Alzheimer's disease. *Lancet.* 2021;397:1577–90.
- Chartier-Harlin MC, Parfitt M, Legrain S, P  rez-Tur J, Brousseau T, Evans A, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. *Human Mol Genet.* 1994;3:569–74.

- Houlden H, Crook R, Backhovens H, Pihar G, Baker M, Hutton M, et al. ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. *Am J Med Genet.* 1998;81:117–21.
- Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. *Neuron.* 2001;32:181–4.
- Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol.* 2013;9:106–18.
- Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. *J Biol Chem.* 2003;278:48529–33.
- Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, et al. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. *Arch Neurol.* 2012;69:757–64.
- Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. *Neuron.* 2009;63:287–303.
- Han SH, Einstein G, Weisgraber KH, Strittmatter WJ, Saunders AM, Pericak-Vance M, et al. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. *J Neuropathol Exp Neurol.* 1994;53:535–44.
- Bao F, Arai H, Matsushita S, Higuchi S, Sasaki H. Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain. *Neuroreport.* 1996;7:1733–9.
- Boschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S. Apolipoprotein E expression by neurons surviving excitotoxic stress. *Neurobiol Dis.* 1999;6:508–14.
- Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. *J Neurosci.* 2006;26:4985–94.
- Darmanis S, Sloan SA, Zhang Y, Enge M, Caneda C, Shuer LM, et al. A survey of human brain transcriptome diversity at the single cell level. *Proc Natl Acad Sci USA.* 2015;112:7285–90.
- Zalocusky KA, Najm R, Taubes AL, Hao Y, Yoon SY, Koutsodendris N, et al. Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease. *Nature Neurosci.* 2021;24:786–98.
- Cardinaux JR, Allaman I, Magistretti PJ. Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. *Glia.* 2000;29:91–97.
- Cortes-Cantelli M, Aguilar-Morante D, Sanz-Sancristobal M, Megias D, Santos A, Perez-Castillo A. Role of C/EBP β transcription factor in adult hippocampal neurogenesis. *PLoS ONE.* 2011;6:e24842.
- Wang ZH, Gong K, Liu X, Zhang Z, Sun X, Wei ZZ, et al. C/EBP β regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer's disease. *Nature Commun.* 2018;9:1784.
- Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. *Nature Med.* 2014;20:1254–62.
- Zhang Z, Song M, Liu X, Su Kang S, Duong DM, Seyfried NT, et al. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease. *Nat Commun.* 2015;6:8762.
- Wang H, Liu X, Chen S, Ye K. Spatiotemporal activation of the C/EBP β / δ -secretase axis regulates the pathogenesis of Alzheimer's disease. *Proc Natl Acad Sci USA.* 2018;115:E12427–e12434.
- Strohmeier R, Shelton J, Lougheed C, Breitkopf T. CCAAT-enhancer binding protein- β expression and elevation in Alzheimer's disease and microglial cell cultures. *PLoS ONE.* 2014;9:e86617.
- Xia Y, Wang ZH, Zhang J, Liu X, Yu SP, Ye KX, et al. C/EBP β is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer's disease. *Mol Psychiatry.* 2021;26:6002–22.
- Wang ZH, Xia Y, Liu P, Liu X, Edgington-Mitchell L, Lei K, et al. ApoE4 activates C/EBP β / δ -secretase with 27-hydroxycholesterol, driving the pathogenesis of Alzheimer's disease. *Prog Neurobiol.* 2021;202:102032.
- Ndoja A, Reja R, Lee SH, Webster JD, Ngu H, Rose CM, et al. Ubiquitin ligase COP1 suppresses neuroinflammation by degrading c/EBP β in microglia. *Cell.* 2020;182:1156–1169.e1112.
- Wang ZH, Xia Y, Wu Z, Kang SS, Zhang JC, Liu P, et al. Neuronal ApoE4 stimulates C/EBP β activation, promoting Alzheimer's disease pathology in a mouse model. *Prog Neurobiol.* 2022;209:102212.
- Lee JE, Han PL. An update of animal models of Alzheimer disease with a re-evaluation of plaque depositions. *Exp Neurobiol.* 2013;22:84–95.
- Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron.* 2003;39:409–21.
- Xia Y, Wang ZH, Zhang Z, Liu X, Yu SP, Wang JZ, et al. Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer's disease. *Prog Neurobiol.* 2021;204:102113.

38. Dallaire-Théroux C, Callahan BL, Potvin O, Saikali S, Duchesne S. Radiological-pathological correlation in Alzheimer's disease: systematic review of antemortem magnetic resonance imaging findings. *J Alzheimer's Dis.* 2017;57:575–601.
39. Chiquita S, Ribeiro M, Castelhana J, Oliveira F, Sereno J, Batista M, et al. A longitudinal multimodal in vivo molecular imaging study of the 3xTg-AD mouse model shows progressive early hippocampal and taurine loss. *Hum Mol Genet.* 2019;28:2174–88.
40. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. *J Neurosci.* 2007;27:10957–68.
41. Ahlemeyer B, Halupczok S, Rodenberg-Frank E, Valerius KP, Baumgart-Vogt E. Endogenous murine amyloid- β peptide assembles into aggregates in the aged C57BL/6J mouse suggesting these animals as a model to study pathogenesis of amyloid- β plaque formation. *J Alzheimer's Dis.* 2018;61:1425–50.
42. Xu G, Ran Y, Fromholt SE, Fu C, Yachnis AT, Golde TE, et al. Murine A β overproduction produces diffuse and compact Alzheimer-type amyloid deposits. *Acta Neuropathol Commun.* 2015;3:72.
43. Krohn M, Bracke A, Avchalamov Y, Schumacher T, Hofrichter J, Paarmann K, et al. Accumulation of murine amyloid- β mimics early Alzheimer's disease. *Brain.* 2015;138:2370–82.
44. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. *Science.* 2006;313:1781–4.
45. Adams SJ, Crook RJ, Deture M, Randle SJ, Innes AE, Yu XZ, et al. Overexpression of wild-type murine tau results in progressive tauopathy and neurodegeneration. *Am J Pathol.* 2009;175:1598–609.
46. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 1991;82:239–59.
47. Lv X, Li W, Luo Y, Wang D, Zhu C, Huang ZX, et al. Exploring the differences between mouse mA β (1–42) and human hA β (1–42) for Alzheimer's disease related properties and neuronal cytotoxicity. *Chem Commun.* 2013;49:5865–7.
48. Dyrks T, Dyrks E, Masters CL, Beyreuther K. Amyloidogenicity of rodent and human beta A4 sequences. *FEBS Lett.* 1993;324:231–6.
49. Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. *Brain.* 2023;146:1152–65.
50. Simrén J, Brum WS, Ashton NJ, Benedet AL, Karikari TK, Kvartsberg H, et al. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals. *Alzheimer's Res Ther.* 2022;14:192.
51. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature.* 2013;501:45–51.
52. Goedert M. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A β , tau, and α -synuclein. *Science.* 2015;349:1255–55.
53. Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. *Nature Neurosci.* 2018;21:1341–9.
54. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. *Nature.* 2008;451:720–4.
55. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, et al. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. *Science.* 2008;321:1686–9.
56. Viola KL, Klein WL. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. *Acta Neuropathol.* 2015;129:183–206.
57. Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. *Nature Rev Neurol.* 2023;19:19–38.
58. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA.* 2000;97:2892–7.
59. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. *Neurobiol Dis.* 2002;9:305–18.
60. Jucker M, Walker LC. Alzheimer's disease: from immunotherapy to immunoprevention. *Cell.* 2023;186:4260–70.
61. Xiong J, Kang SS, Wang M, Wang Z, Xia Y, Liao J, et al. FSH and ApoE4 contribute to Alzheimer's disease-like pathogenesis via C/EBP β / δ -secretase in female mice. *Nature Commun.* 2023;14:6577.
62. Koutsodendris N, Blumenfeld J, Agrawal A, Traglia M, Grone B, Zilberter M, et al. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. *Nature Aging.* 2023;3:275–96.
63. Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. *Nature Med.* 2018;24:647–57.
64. Qian Z, Li H, Yang H, Yang Q, Lu Z, Wang L, et al. Osteocalcin attenuates oligodendrocyte differentiation and myelination via GPR37 signaling in the mouse brain. *Sci Adv.* 2021;7:eabi5811.
65. Qian Z, Li B, Meng X, Liao J, Wang G, Li Y, et al. Inhibition of asparagine endopeptidase (AEP) effectively treats sporadic Alzheimer's disease in mice. *Neuropsychopharmacology.* 2024;49:620–630.
66. Casali BT, Landreth GE. A β Extraction from murine brain homogenates. *Bio-protocol.* 2016;6:e1787.
67. Sahara N, Kimura T. Biochemical properties of pathology-related tau species in tauopathy brains: an extraction protocol for tau oligomers and aggregates. *Methods Mol Biol.* 2018;1779:435–45.

AUTHOR CONTRIBUTIONS

KY conceived the project, designed the experiments, analyzed the data, and wrote the manuscript. ZQ designed and performed most of the experiments, analyzed the data and wrote the manuscript. BL and XM performed the SiMoA experiments. ZW developed the double transgenic mice. ZK and FY performed the PET experiment. YL assisted with data analysis and interpretation. All the authors approved the manuscript.

FUNDING

This work was supported by Start-up fund from SIAT and the National Natural Science Foundation of China (32330040) to K. Y., the Guangdong Basic and Applied Basic Research Foundation (2023A1515030296), and the Shenzhen Government Basic Research Program (JCYJ20220531100802005) to Z.Q. and the National Natural Science Foundation of China (32200928) to Y.L.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41380-024-02565-x>.

Correspondence and requests for materials should be addressed to Keqiang Ye.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024